Prediction of mortality in patients with heart failure and systolic dysfunction

Current Cardiology Reports

Volumn 10, Issue 3, 2008, Pages 198-205

  Levy, Wayne C ^a   Linker, David T ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ASSISTED CIRCULATION; ASSISTIVE TECHNOLOGY DEVICE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE MODEL; EXERCISE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MORTALITY; MULTIVARIATE ANALYSIS; OUTPATIENT; PREDICTION; PROTEIN BLOOD LEVEL; QRS COMPLEX; REVIEW; RISK ASSESSMENT; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; TERMINAL CARE; TREATMENT INDICATION; FORECASTING; RISK FACTOR; STATISTICAL MODEL; TIME;

FORECASTING; HEART FAILURE, SYSTOLIC; HOSPITAL MORTALITY; HUMANS; MODELS, STATISTICAL; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 45849148878     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0034-0     Document Type: Review

References (50)

1. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273: 1450-1456.
2. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003, 362: 759-766.
3. Goldstein S, Hjalmarson A: The mortality effect of metoprolol CR/XL in patients with heart failure: Results of the MERIT-HF Trial. Clin Cardiol 1999, 22(Suppl 5): V30-V35.
4. Eichhorn EJ, Bristow MR: The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2001, 2: 20-23.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial [no authors listed]. Lancet 1999, 353: 9-13.
6. Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362: 7-13.
7. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348: 1309-1321.
8. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341: 709-717.
9. Bristow MR, Saxon LA, Boehmer J, et al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350: 2140-2150.
10. Cleland JG, Daubert JC, Erdmann E, et al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352: 1539-1549.
11. Bardy GH, Lee KL, Mark DB, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352: 225-237.
12. Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345: 1435-1443.
13. Levy WC, Mozaffarian D, Linker DT, et al.: The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation 2006, 113: 1424-1433.
14. Alexander M, Grumbach K, Remy L, et al.: Congestive heart failure hospitalizations and survival in California: Patterns according to race/ ethnicity. Am Heart J 1999, 137: 919-927.
15. Cooper LT, Jr, Berry GJ, Shabetai R: Idiopathic giant-cell myocarditis - natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997, 336: 1860-1866.
16. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al.: Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000, 342: 690-695.
17. Bittner V, Weiner DH, Yusuf S, et al.: Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA 1993, 270: 1702-1707.
18. Mancini DM, Eisen H, Kussmaul W, et al.: Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991, 83: 778-786.
19. O'Neill JO, Young JB, Pothier CE, et al.: Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 2005, 111: 2313-2318.
20. Itoh H, Koike A, Taniguchi K, et al.: Severity and pathophysiology of heart failure on the basis of anaerobic threshold (AT) and related parameters. Jpn Circ J 1989, 53: 146-154.
21. Deswal A, Petersen NJ, Feldman AM, et al.: Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103: 2055-2059.
22. Latini R, Masson S, Anand I, et al.: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004, 25: 292-299.
23. Anand IS, Latini R, Florea VG, et al.: C-reactive protein in heart failure: Prognostic value and the effect of valsartan. Circulation 2005, 112: 1428-1434.
24. Masson S, Latini R, Anand IS, et al.: The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2006, 12: 375-380.
25. Horwich TB, Patel J, MacLellan WR, et al.: Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003, 108: 833-838.
26. Latini R, Masson S, Anand IS, et al.: Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116: 1242-1249.
27. Masson S, Latini R, Anand IS, et al.: Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52: 1528-1538.
28. Packer M, Lee WH, Kessler PD, et al.: Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 1987, 75: IV80-IV92.
29. Anker SD, Doehner W, Rauchhaus M, et al.: Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003, 107: 1991-1997.
30. Mozaffarian D, Nye R, Levy WC: Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004, 93: 1124-1129.
31. Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003, 41: 1933-1939.
32. Huehnergarth KV, Mozaffarian D, Sullivan MD, et al.: Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol 2005, 95: 1492-1495.
33. Klein L, O'Connor CM, Leimberger JD, et al.: Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005, 111: 2454-2460.
34. Fonarow GC, Adams KF, Jr, Abraham WT, et al.: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293: 572-580.
35. Kalantar-Zadeh K, Block G, Horwich T, et al.: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004, 43: 1439-1444.
36. Rauchhaus M, Clark AL, Doehner W, et al.: The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003, 42: 1933-1940.
37. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 2000, 356: 930-933.
38. D'Agostino RB, Sr, Grundy S, Sullivan LM, et al.: Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001, 286: 180-187.
39. Lee DS, Austin PC, Rouleau JL, et al.: Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 2003, 290: 2581-2587.
40. Rector TS, Ringwala SN, Anand IS: Validation of a risk score for dying within 1 year of an admission for heart failure. J Card Fail 2006, 12: 276-280.
41. Auble TE, Hsieh M, McCausland JB, et al.: Comparison of four clinical prediction rules for estimating risk in heart failure. Ann Emerg Med 2007, 50: 127-135, 135.e1-135.e2.
42. May HT, Horne BD, Levy WC, et al.: Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol 2007, 100: 697-700.
43. Levy WC, Aaronson K, Dardas T, et al.: Does peak oxygen consumption add to the Seattle Heart Failure Model? Circulation 2007, 116: II-505.
44. Ahmed A, Rich MW, Sanders PW, et al.: Chronic kidney disease associated mortality in diastolic versus systolic heart failure: A propensity matched study. Am J Cardiol 2007, 99: 393-398.
45. Wang TJ, Gona P, Larson MG, et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355: 2631-2639.
46. Levy WC: Can B-type natriuretic peptides replace heart failure risk models? Eur J Heart Fail 2008, In press.
47. Mozaffarian D, Anker SD, Anand I, et al.: Prediction of mode of death in heart failure: The Seattle Heart Failure Model. Circulation 2007, 116: 392-398.
48. Lindenfeld J, Feldman AM, Saxon L, et al.: Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007, 115: 204-212.
49. Pocock SJ, Wang D, Pfeffer MA, et al.: Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006, 27: 65-75.
50. Pfister R, Diedrichs J, Schiedermair A, et al.: Prognostic impact of NT-pro-BP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 2008, In press.